185 related articles for article (PubMed ID: 34043482)
1. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy.
Enell Smith K; Deronic A; Hägerbrand K; Norlén P; Ellmark P
Expert Opin Biol Ther; 2021 Dec; 21(12):1635-1646. PubMed ID: 34043482
[No Abstract] [Full Text] [Related]
2. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
3. Next-generation CD40 agonists for cancer immunotherapy.
Andersson H; Nyesiga B; Hermodsson T; Enell Smith K; Hägerbrand K; Lindstedt M; Ellmark P
Expert Opin Biol Ther; 2024 May; 24(5):351-363. PubMed ID: 38764393
[TBL] [Abstract][Full Text] [Related]
4. PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8
Chaib M; Sipe LM; Yarbro JR; Bohm MS; Counts BR; Tanveer U; Pingili AK; Daria D; Marion TN; Carson JA; Thomas PG; Makowski L
Cancer Lett; 2022 Apr; 531():98-108. PubMed ID: 35074498
[TBL] [Abstract][Full Text] [Related]
5. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models.
Wang B; Liu Y; Yuan R; Dou X; Qian N; Pan X; Xu G; Xu Q; Dong B; Yang C; Li H; Wang J; Bai G; Liu L; Gao X
Cancer Immunol Immunother; 2023 Dec; 72(12):4015-4030. PubMed ID: 37863852
[TBL] [Abstract][Full Text] [Related]
6. Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy.
Salomon R; Dahan R
Front Immunol; 2022; 13():940674. PubMed ID: 35911742
[TBL] [Abstract][Full Text] [Related]
7. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation.
Sum E; Rapp M; Dürr H; Mazumdar A; Romero PJ; Trumpfheller C; Umaña P
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292514
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting.
Salomon R; Rotem H; Katzenelenbogen Y; Weiner A; Cohen Saban N; Feferman T; Amit I; Dahan R
Nat Cancer; 2022 Mar; 3(3):287-302. PubMed ID: 35190724
[TBL] [Abstract][Full Text] [Related]
9. Agonistic CD40 antibodies and cancer therapy.
Vonderheide RH; Glennie MJ
Clin Cancer Res; 2013 Mar; 19(5):1035-43. PubMed ID: 23460534
[TBL] [Abstract][Full Text] [Related]
10. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application.
Filbert EL; Björck PK; Srivastava MK; Bahjat FR; Yang X
Cancer Immunol Immunother; 2021 Jul; 70(7):1853-1865. PubMed ID: 33392713
[TBL] [Abstract][Full Text] [Related]
11. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response.
Osada T; Nagawa H; Takahashi T; Tsuno NH; Kitayama J; Shibata Y
J Immunother; 2002; 25(2):176-84. PubMed ID: 12074047
[TBL] [Abstract][Full Text] [Related]
13. The use of agonistic anti-CD40 therapy in treatments for cancer.
Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
[TBL] [Abstract][Full Text] [Related]
14. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
Proc Natl Acad Sci U S A; 2023 Aug; 120(35):e2306782120. PubMed ID: 37607227
[TBL] [Abstract][Full Text] [Related]
15. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation.
French RR; Taraban VY; Crowther GR; Rowley TF; Gray JC; Johnson PW; Tutt AL; Al-Shamkhani A; Glennie MJ
Blood; 2007 Jun; 109(11):4810-5. PubMed ID: 17311995
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the potential of CD40 agonism in cancer therapy.
Zhou Y; Richmond A; Yan C
Cytokine Growth Factor Rev; 2024 Feb; 75():40-56. PubMed ID: 38102001
[TBL] [Abstract][Full Text] [Related]
17. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs.
Taraban VY; Rowley TF; Al-Shamkhani A
J Immunol; 2004 Dec; 173(11):6542-6. PubMed ID: 15557144
[TBL] [Abstract][Full Text] [Related]
19. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
Jiang Q; Weiss JM; Back T; Chan T; Ortaldo JR; Guichard S; Wiltrout RH
Cancer Res; 2011 Jun; 71(12):4074-84. PubMed ID: 21540234
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Beatty GL; Li Y; Long KB
Expert Rev Anticancer Ther; 2017 Feb; 17(2):175-186. PubMed ID: 27927088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]